IRRAS is a commercial stage medical technology company that is currently focused on the design, development and commercialization of innovative solutions to facilitate surgical procedures for the treatment of hemorrhagic stroke and chronic subdural hematoma. Our transformational medical device product, the IRRAflow™ system, supports the control and management of intracranial fluid through its proprietary platform technology, which is a fully integrated, closed-circuit medical device system, that significantly reduces catheter blockage and infections.

Since the commercial launch in the European Union in May of 2017 for the monitoring of intracranial pressure (ICP) and intracranial fluid management, the IRRAflow™system has dramatically improved patient outcomes, reduced patient days in the hospital and provided significant health economic benefits to hospitals and healthcare providers. Subject to regulatory approval, IRRAS is seeking to initiate sales and marketing in the United States during 2018.